Username Password
S&P 500: 1,317.45 Change: +0.03%
Zacks_Analysts
At least 5 active picks are required to calculate a P&P score.

Zacks_Analysts' Blog : Meridian Intros HyperPAGE II Marker - Analyst Blog

Date January 19, 2012    Comments Comments (0)    Rate this post Recommend This Post (12)   
Bookmark and Share
Abuse this post  Report Abuse
Please report this as abuse only if you believe it violates People And Picks  Terms of Use
You must log in to send an abuse report.
Share ThisShare This


Bioline, a fully owned subsidiary of diagnostic test kits maker Meridian Bioscience (VIVO), has broadened its HyperPAGE line of prestained molecular weight protein markers with the launch of the new HyperPAGE II protein marker.



HyperPAGE II, a broad range protein marker, is prestained with different fluorescent dyes and contains nine highly purified protein bands with molecular weights ranging from 10 to 250kDa (kilodalton). The fluorescence dyes facilitate easy identification and orientation of the protein bands while performing protein electrophoresis (a method for analyzing proteins). HyperPAGE II is available in a convenient, ready-to-use format.



HyperPAGE II is geared to monitor efficiency in protein electrophoresis and protein transfer from gel to membrane in Western blotting (a widely used method to detect specific protein in a sample). It is also suitable for measuring the molecular weight of protein samples.



Cincinnati-based Meridian specializes in developing diagnostic test kits for multiple serious and infectious diseases. The company’s diagnostics business faces strong competition from Abbott Laboratories (ABT), Becton, Dickinson and Company (BDX), Thermo Fisher (TMO) and Siemens (SI).



Meridian’s $23.3 million acquisition of London-based molecular biology reagents maker Bioline in July 2010 has unlocked opportunities for growth through expanded product range and geographic expansion.



Meridian, in August 2011, released its outlook for fiscal 2012. The company hopes that sales for the year would be boosted by its illumigene molecular tests and Bioline products as well as its foodborne and H. pylori tests.



Meridian is optimistic that sustained adoption of the illumigene platform, growth in core products and opportunities in Europe will help it drive significant growth in sales and earnings in fiscal 2012 and beyond.



Read the full analyst report on "VIVO"
Read the full analyst report on "SI"
Read the full analyst report on "TMO"
Read the full analyst report on "BDX"
Read the full analyst report on "ABT"
Zacks Investment Research
Tags : VIVO   PAGE   II   ABT   BDX   TMO   SI  

Want to comment on this post? Sign up now. It's FREE!
Already registered? Log In.
Sponsored Links